Clinical Trial Update: Intermediate Size Patient Population Expanded Access Protocol to Evaluate HB-adMSCs for the Treatment of Patients With Traumatic or Nontraumatic Brain Injury

View source ↗

Summary

Hope Biosciences is expanding the intermediate-size patient population for an expanded access protocol using HB-adMSCs to treat traumatic or nontraumatic brain …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-traumatic Brain Injury
• Traumatic Brain Injury

Drugs mentioned

• HB-adMSCs (autologous adipose-derived mesenchymal stem cells)

Snippet

Sponsor: Hope Biosciences Research Foundation | Conditions: Brain Injury | Status: AVAILABLE